{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:47:01Z","timestamp":1785192421711,"version":"3.55.0"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for BDQ-resistant TB. This study aims to share experience in managing primary BDQ-resistant TB.<jats:bold>METHODS:<\/jats:bold>\n We performed a retrospective study of patients treated for RR-TB in Karakalpakstan, Uzbekistan, from January 2017 to March 2022. We identified patients with resistance to BDQ with no history of BDQ exposure. We describe baseline characteristics, treatment and follow-up of these patients.<jats:bold>RESULTS:<\/jats:bold>\n Twelve of the 1,930 patients (0.6%) had baseline samples resistant to BDQ with no history of BDQ exposure, 75% (9\/12) of whom had been previously treated for TB. Ten (83.3%) were resistant to fluoroquinolones; respectively 66% and 50% had culture conversion by Month 3 and Month 6. The interim\n treatment outcomes were as follows: unfavourable treatment outcomes (3\/12, 25%), favourable outcomes (2\/12, 17%); the remaining seven (58%) were continuing treatment.<jats:bold>CONCLUSIONS:<\/jats:bold> A large proportion of the cases had previously been treated for TB and had TB resistant to quinolone.\n Both patients who had not experienced culture conversion by Month 3 had an unfavourable treatment outcome. Therefore, we recommend monthly monitoring of culture status for patients on treatment regimens for BDQ resistance.<\/jats:p>","DOI":"10.5588\/ijtld.22.0536","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T04:31:00Z","timestamp":1683261060000},"page":"381-386","source":"Crossref","is-referenced-by-count":9,"title":["Primary bedaquiline resistance in Karakalpakstan, Uzbekistan"],"prefix":"10.5588","volume":"27","author":[{"given":"S.","family":"Moe","sequence":"first","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Rekart","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sholpan","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ismailov","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oluya","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bayniyazova","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res, Karakalpakstan, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zinaida","sequence":"additional","affiliation":[{"name":"Republican Center of Tuberculosis and Pulmonology, Nukus, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nargiza","sequence":"additional","affiliation":[{"name":"Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology, Tashkent, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gomez-Restrepo","sequence":"additional","affiliation":[{"name":"Medecins Sans Fronti\u00e8res (MSF), Tashkent, Uzbekistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sitali","sequence":"additional","affiliation":[{"name":"MSF, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sinha","sequence":"additional","affiliation":[{"name":"MSF, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2023\/00000027\/00000005\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T05:13:34Z","timestamp":1687497214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.22.0536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"alternative-id":["1027-3719(20230501)27:5L.381;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.22.0536","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}